DE69638058D1 - Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie - Google Patents

Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie

Info

Publication number
DE69638058D1
DE69638058D1 DE69638058T DE69638058T DE69638058D1 DE 69638058 D1 DE69638058 D1 DE 69638058D1 DE 69638058 T DE69638058 T DE 69638058T DE 69638058 T DE69638058 T DE 69638058T DE 69638058 D1 DE69638058 D1 DE 69638058D1
Authority
DE
Germany
Prior art keywords
gene therapy
adenoviral
possibility
adenovirus
human recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69638058T
Other languages
English (en)
Inventor
Frits Jacobus Fallaux
Robert Cornelis Hoeben
Abraham Bout
Domenico Valerio
Der Eb Alex Jan Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26139401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69638058(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Application granted granted Critical
Publication of DE69638058D1 publication Critical patent/DE69638058D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69638058T 1995-06-15 1996-06-14 Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie Expired - Lifetime DE69638058D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95201611 1995-06-15
EP95201728 1995-06-26

Publications (1)

Publication Number Publication Date
DE69638058D1 true DE69638058D1 (de) 2009-11-26

Family

ID=26139401

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69633565T Expired - Lifetime DE69633565T3 (de) 1995-06-15 1996-06-14 Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
DE69638058T Expired - Lifetime DE69638058D1 (de) 1995-06-15 1996-06-14 Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69633565T Expired - Lifetime DE69633565T3 (de) 1995-06-15 1996-06-14 Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie

Country Status (15)

Country Link
US (10) US5994128A (de)
EP (2) EP1445322B2 (de)
JP (2) JP4051416B2 (de)
KR (2) KR100470180B1 (de)
AT (2) ATE278794T1 (de)
AU (1) AU731767B2 (de)
CA (1) CA2222140C (de)
DE (2) DE69633565T3 (de)
DK (2) DK0833934T4 (de)
ES (2) ES2231813T5 (de)
HK (1) HK1064406A1 (de)
IL (3) IL160406A0 (de)
PT (2) PT833934E (de)
SI (2) SI0833934T2 (de)
WO (1) WO1997000326A1 (de)

Families Citing this family (356)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0872552A1 (de) * 1997-04-15 1998-10-21 Leadd B.V. Genabgabe-Vehikel die das Apoptosis VP2 induzierendes Protein und/oder Apoptin exprimiert
NL9101680A (nl) 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6080569A (en) * 1993-06-24 2000-06-27 Merck & Co., Inc. Adenovirus vectors generated from helper viruses and helper-dependent vectors
ES2224113T5 (es) * 1994-02-16 2009-05-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Polipeptido antigenico asociado al melanoma, epitopos del mismo y vacunas contra melanoma.
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ATE246252T1 (de) 1994-08-16 2003-08-15 Crucell Holland Bv Von adenovirus abgeleitete rekombinante vektoren, für gentherapie
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
CA2224907A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
US6140103A (en) * 1995-12-01 2000-10-31 Introgene B.V. Regulated protein expression in stably transfected mammalian cells
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6110744A (en) 1996-11-13 2000-08-29 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
WO1998024924A1 (en) 1996-12-05 1998-06-11 Introgene B.V. Genetic modification of primate hemopoietic repopulating stem cells
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
JP2000509614A (ja) 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド アデノウイルスｅ１−相補性細胞系
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
WO1999027123A2 (en) * 1997-11-26 1999-06-03 Board Of Regents, The University Of Texas System Modified sv40 viral vectors
EP1042494A1 (de) 1997-12-23 2000-10-11 Introgene B.V. Chimere rekombinante vektoren abgeleitet von adeno-assoziiertem virus und adenovirus für die chromosomale integration von fremd-dns in zielzellen
DE69933856D1 (de) 1998-02-13 2006-12-14 Koester Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
EP0959136A1 (de) 1998-05-20 1999-11-24 Introgene B.V. Bei einem transporter von kationischen Aminosaüren zielgerichtete Darreichung
US6413776B1 (en) * 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
EP1124976A1 (de) * 1998-10-27 2001-08-22 Crucell Holland B.V. Verbesserte produktion von aav-vektoren
IT1302403B1 (it) * 1998-11-06 2000-09-05 Angeletti P Ist Richerche Bio Cellule per la produzione di vettori adenovirali difettivi, metodoper la loro preparazione e loro uso.
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
IL133032A (en) * 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
EP1016726A1 (de) * 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
WO2000052186A1 (en) * 1999-03-04 2000-09-08 Introgene B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
SI1161548T2 (sl) † 1999-04-15 2010-02-26 Crucell Holland Bv Priprava rekombinantnega proteina v humani celici z uporabo sekvenc, ki kodirajo adenovirusni E1 protein
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US20060099685A1 (en) * 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US8236561B2 (en) * 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
CA2371069A1 (en) * 1999-04-23 2001-02-01 Crucell Holland B.V. Means and methods for nucleic acid transfer
DE60014489T3 (de) 1999-05-17 2010-08-12 Crucell Holland B.V. Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7468181B2 (en) * 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
JP2003530307A (ja) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン
EP1067190A1 (de) * 1999-07-09 2001-01-10 Introgene B.V. Gentherapie zur Erhöhung und/oder Induktion der Angiogenese
CA2384439A1 (en) * 1999-09-10 2001-03-22 Crucell Holland B.V. Modified adenoviral vectors for use in gene therapy
EP1083229A1 (de) * 1999-09-10 2001-03-14 Introgene B.V. Veränderte adenovirale Vektoren für die Gentherapie
EP1083228A1 (de) * 1999-09-10 2001-03-14 Introgene B.V. Veränderte adenovirale Vektoren für die Gentherapie
US6365394B1 (en) * 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
DE19955558C2 (de) * 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
CA2393844A1 (en) * 1999-12-14 2001-06-21 Genovo, Inc. Methods and compositions for the manufacture of replication incompetent adenovirus
EP1248653A2 (de) * 2000-01-07 2002-10-16 Stichting Klinische Farmacologie Groningen Gentherapie zur förderung von angiogenese sowie zur behandlung von herzinsuffienz
US7132277B1 (en) 2000-01-31 2006-11-07 Merck & Co., Inc. Helper dependent vector system for gene therapy
WO2001072994A2 (en) * 2000-03-24 2001-10-04 Cell Genesys, Inc Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
EP1157999A1 (de) * 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
KR20010064682A (ko) * 2000-07-01 2001-07-11 김재호 Ｅ1ｂ가 감쇠된 아데노바이러스를 이용한 ｃｄ／5－ｆｃ및 ｈｓｖ－1 ｔｋ／ｇｃｖ의 이중 자멸 유전자 시스템
US20020164333A1 (en) * 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US20040101957A1 (en) * 2001-09-14 2004-05-27 Emini Emilio A. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
EP1322774A2 (de) * 2000-09-20 2003-07-02 Crucell Holland B.V. Transduktion von dendritischen zellen durch verwendung der adenovirenvektoren
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
US6573092B1 (en) 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
WO2002068627A2 (en) * 2001-02-23 2002-09-06 Novartis Ag Vector constucts
ATE434936T1 (de) 2001-03-14 2009-07-15 Myriad Genetics Inc Tsg101-gag-wechselwirkung und ihre verwendung
EP1256803A1 (de) * 2001-05-07 2002-11-13 Crucell Holland B.V. Verfahren zur Identifizierung von antiviralen Verbindungen
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20030119771A1 (en) * 2001-08-22 2003-06-26 Rompaey Luc Van Modulators of bone homeostasis identified in a high-throughput screen
CA2461380C (en) * 2001-10-11 2011-03-22 Merck & Co., Inc. Hepatitis c virus vaccine
EP2172552A3 (de) 2001-10-11 2010-07-21 Merck Sharp & Dohme Corp. Rekombinante Nukleinsäuren beinhaltend Regionen von AD6
JP4583029B2 (ja) 2001-10-29 2010-11-17 クルセル ホランド ベー ヴェー 所定の翻訳後修飾を有する蛋白質の製造方法及び製造手段
AU2002351444B2 (en) 2001-12-07 2008-02-21 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
ES2307807T3 (es) * 2001-12-17 2008-12-01 Crucell Holland B.V. Produccion de fragmentos f(ab')2 en celulas de mamiferos.
WO2003057916A2 (en) 2002-01-09 2003-07-17 Riken Cancer profiles
EP1516055A4 (de) * 2002-01-24 2007-08-08 Scripps Research Inst Faserschaftmodifikationen für effizientes zielen
ATE324467T1 (de) * 2002-02-20 2006-05-15 Merck & Co Inc Verfahren zur konzentrationsbestimmung von adenoviruspartikeln
US7282567B2 (en) 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
DE60325184D1 (de) 2002-03-01 2009-01-22 Immunomedics Inc Rs7 antikörper
EP1492891B1 (de) * 2002-03-29 2008-02-20 Merck & Co., Inc. Verfahren zur virusproduktion
AU2003228466A1 (en) * 2002-04-08 2003-10-27 The Johns Hopkins University Packaging cell line for diphtheria toxin expressing non-replicating adenovirus
JP4495588B2 (ja) * 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 安定なアデノウイルスベクターおよびその増殖方法
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
WO2004037294A2 (en) 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) * 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US20050221493A1 (en) * 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
AU2003290453A1 (en) * 2002-12-20 2004-07-14 Chromagenics B.V. Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
WO2004092396A2 (en) * 2003-04-15 2004-10-28 Novartis Ag Flap endonuclease 1 (fen1) regulatory sequences and uses thereof
WO2004092397A2 (en) * 2003-04-15 2004-10-28 Novartis Ag Tmprss2 regulatory sequences and uses thereof
NZ542585A (en) 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
DK1626992T3 (da) * 2003-05-23 2010-09-20 Crucell Holland Bv Produktion af rekombinant IgM i PER.C6-celler
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
JP4644663B2 (ja) * 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
EP1639090A4 (de) 2003-06-09 2008-04-16 Univ Michigan Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
DK1670925T3 (da) * 2003-10-02 2013-07-08 Crucell Holland Bv Pakningsceller til rekombinat adenovirus
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
EP1528101A1 (de) 2003-11-03 2005-05-04 ProBioGen AG Immortalisierte Vogel-Zelllinien für die Produktion von Viren
WO2005051432A1 (en) * 2003-11-14 2005-06-09 Genvec, Inc. Therapeutic regimen for treating cancer
LT2163260T (lt) 2004-01-23 2017-06-26 Msd Italia S.R.L. Šimpanzės adenoviruso vakcinos nešikliai
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
ES2329607T3 (es) * 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
CN1972958B (zh) 2004-04-12 2013-01-23 美国政府卫生与公共服务部 应用腺病毒载体诱导免疫应答的方法
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
JP2008500364A (ja) * 2004-05-25 2008-01-10 キメラコア， インコーポレイテッド 自己集合性ナノ粒子薬物送達システム
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
ES2347340T3 (es) 2004-09-13 2010-10-28 Genzyme Corporation Construcciones multimericas.
PL2572661T3 (pl) 2004-10-05 2020-06-01 Genzyme Corporation Stopniowana kaniula
AU2005294265A1 (en) 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
EP1805213B1 (de) * 2004-10-28 2015-11-18 University of Pittsburgh - Of the Commonwealth System of Higher Education Peripher verabreichte gentherapie mit glutaminsäure-decarboxylase gegen schmerzen aufgrund einer rückenmarksverletzung
US8999667B2 (en) * 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
CA2581422C (en) 2004-11-08 2012-05-22 Chromagenics B.V. Selection of host cells expressing protein at high levels
SI1809750T1 (sl) 2004-11-08 2012-08-31 Chromagenics Bv Izbira gostiteljskih celic, ki imajo visok nivo izraĹľanja proteina
US8039230B2 (en) * 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20060195935A1 (en) * 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
EP1831352B1 (de) * 2004-12-13 2011-07-13 CANJI, Inc. Zellinien zur produktion von replikationsdefektem adenovirus
EP1856526A4 (de) 2005-01-20 2008-11-12 Univ Rochester Mit thioredoxin interagierendes protein (txnip) als regulator der gefässfunktion
JP2008538894A (ja) * 2005-02-11 2008-11-13 メルク エンド カムパニー インコーポレーテッド アデノウイルス血清型２６ベクター、核酸およびそれにより製造されたウイルス
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
ES2696824T3 (es) 2005-05-31 2019-01-18 Univ Colorado Regents Métodos para suministrar genes
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1893636A2 (de) * 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis-c-virus-nukleinsäureimpfstoff
JP5137829B2 (ja) * 2005-07-22 2013-02-06 クルセル ホランド ベー ヴェー コロナウイルス類生産用の細胞系
US8450055B2 (en) * 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
US9651543B2 (en) 2005-08-31 2017-05-16 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
EP1929021A2 (de) 2005-08-31 2008-06-11 Genvec, Inc. Malariaimpfstoffe auf adenovirusvektorbasis
JP5512125B2 (ja) 2005-09-12 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
US8652467B2 (en) * 2005-10-14 2014-02-18 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
JP2009513708A (ja) 2005-10-31 2009-04-02 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5129149B2 (ja) * 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
JP5097714B2 (ja) * 2005-12-12 2012-12-12 カンジ，インコーポレイテッド Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
PT1988823T (pt) 2006-02-09 2018-11-22 Genzyme Corp Administração intraventricular lenta
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
US7968700B2 (en) * 2006-03-20 2011-06-28 Chromagenics B.V. Expression augmenting DNA fragments, use thereof, and methods for finding thereof
SMP200800060B (it) 2006-04-07 2009-07-14 Procter & Gamble Anticorpi che legano la proteina umana tirosina fosfatasi beta (hptbeta) e loro usi
AU2007348315A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating B- cell malignancies
WO2007149594A2 (en) * 2006-06-23 2007-12-27 Quintessence Biosciences, Inc. Modified ribonucleases
US20100159450A1 (en) 2006-06-23 2010-06-24 Susanne Wagner Dpyd gene variants and use thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
PL2041259T3 (pl) 2006-07-14 2016-04-29 Dpx Holdings Bv Udoskonalony sposób hodowania komórek
US8298801B2 (en) 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
US20080261216A1 (en) * 2006-09-08 2008-10-23 The Regents Of The University Of Michigan HERV Group II Viruses In Lymphoma And Cancer
US20100278870A1 (en) * 2007-01-09 2010-11-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Adenoviral vector-based malaria vaccines
US11371194B2 (en) * 2007-01-19 2022-06-28 Brock Usa, Llc Base for turf system
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
ATE495239T1 (de) * 2007-03-09 2011-01-15 Vectorlogics Inc Zellen für adenovirusvektor- und proteinherstellung
CA2683063A1 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
EP3018216B1 (de) 2007-07-06 2018-09-12 The Regents Of The University Of Michigan Rezidivierende genfusionen bei prostatakrebs
EP2597464B1 (de) 2007-08-16 2015-02-25 The Regents of the University of Michigan Metabolomische Profilierung von Prostatakrebs
DE102007041655A1 (de) 2007-09-03 2009-03-05 Medicyte Gmbh Vermehrung von primären Zellen und deren Verwendung
EP2205271B1 (de) * 2007-10-08 2014-05-21 Quintessence Biosciences, Inc. Zusammensetzungen und verfahren für therapien auf ribonukleasebasis
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
US8518884B2 (en) 2008-04-25 2013-08-27 Northwestern University Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
US8193151B2 (en) * 2008-04-25 2012-06-05 Northwestern University Methods for treating atrial or ventricular arrhythmias
EP2307538B1 (de) * 2008-07-15 2015-10-21 Crucell Holland B.V. Skalierbares verfahren zur kultivierung per.c6 zellen und herstellung von produkten daraus
EP2342321B1 (de) 2008-09-17 2018-04-11 Isogenis, Inc. Konstruktion von genzuführungsvektoren auf basis eines vollständig deletierten adenovirus und verwendungen davon
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
BRPI0920743A2 (pt) 2008-10-01 2016-09-20 Quintessence Biosciences Inc ribonucleases terapeuticas
US20110184154A1 (en) * 2008-10-17 2011-07-28 Percivia Llc Cell broth clarification and host cell protein removal
WO2010060719A1 (en) * 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
WO2010081001A2 (en) 2009-01-09 2010-07-15 The Regents Of The University Of Michigan Recurrent gene fusions in cancer
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
BRPI1006901A2 (pt) 2009-01-20 2016-02-16 Transgène S A método ex vivo e kit para testar se um paciente responderá terapeuticamente a um método de tratamento, e, uso de níveis de sicam-1 em uma amostra de sangue
WO2010107991A2 (en) 2009-03-18 2010-09-23 Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
HUE026194T2 (en) 2009-03-24 2016-05-30 Transgene Sa Biomarker for checking patients
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
RU2555340C2 (ru) 2009-04-17 2015-07-10 Трансжене Са Биомаркер для мониторинга пациентов
DK2421895T3 (en) 2009-04-23 2016-01-25 Crucell Holland Bv Recombinant human alpha 1-antitrypsin
CA3120504A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
PL2451279T3 (pl) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
EP2451935A2 (de) 2009-07-08 2012-05-16 Glycotope GmbH Perfusionsbioreaktor
DK2452194T3 (en) 2009-07-10 2015-11-30 Transgene Sa Biomarker PATIENT SELECTION AND RELATED PRACTICES
SG177655A1 (en) 2009-07-16 2012-02-28 Crucell Holland Bv Production of polio virus at high titers for vaccine production
EP2461826A2 (de) 2009-08-07 2012-06-13 Transgene SA Zusammensetzung zur behandlung von hbv-infektionen
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
US8470585B2 (en) * 2009-10-15 2013-06-25 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
JP5393896B2 (ja) * 2009-10-15 2014-01-22 クルセル ホランド ベー ヴェー アデノウイルス粒子の精製方法
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
AU2010314842A1 (en) 2009-11-09 2012-05-31 Genvec, Inc. Methods of propagating monkey adenoviral vectors
ES2524886T3 (es) 2010-01-08 2014-12-15 Profibrix Bv Preparados de fibrinógeno enriquecidos en fibrinógeno con una cadena alfa extendida
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
US9682133B2 (en) 2010-03-17 2017-06-20 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
EP2548025A4 (de) 2010-03-17 2013-09-25 Univ Michigan Verwendung von phagenepitopen zur profilierung einer immunreaktion
TWI688395B (zh) 2010-03-23 2020-03-21 英翠克頌公司 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
CN103118702A (zh) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 活动性结核病的治疗性接种
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
DE102010041958A1 (de) 2010-10-04 2012-04-05 Medicyte Gmbh Geeignete Hepatozyten für in-vitro Genotoxitätstests
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
EP2654786B1 (de) 2010-12-20 2019-02-20 GenVec, Inc. Auf adenovirusvektor basierender impfstoff gegen denguefieber
EP2658567A4 (de) 2010-12-28 2014-09-24 Univ Rochester Verfahren zur modifikation einer insulinsignalübertragung mittels biliverdinreduktase (bvr) und bvr-abgeleiteten peptiden
EP2670426B1 (de) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodale trail-moleküle und ihre verwendungen in zelltherapien
WO2012122025A2 (en) 2011-03-04 2012-09-13 Intrexon Corporation Vectors conditionally expressing protein
WO2013001372A2 (en) 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
ES2592628T3 (es) 2011-07-06 2016-11-30 Sykehuset Sorlandet Hf Terapia dirigida al receptor del factor de crecimiento epidérmico (EGFR)
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
JP2014527072A (ja) 2011-09-09 2014-10-09 バイオメド リアルティー， エル．ピー． ウイルスタンパク質の集合を制御するための方法および組成物
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
US9580476B2 (en) 2011-10-05 2017-02-28 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (RSV) vaccine
CN107574154A (zh) 2011-10-05 2018-01-12 金维克有限公司 猴(大猩猩)腺病毒或腺病毒载体及其使用方法
EP2764012B1 (de) 2011-10-05 2022-02-23 GenVec, Inc. Adenovirusvektoren und verwendungsverfahren dafür
BR112014008249B1 (pt) 2011-10-05 2022-03-15 Genvec Inc Adenovírus ou vetor adenoviral e composição com os mesmos
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
KR101427200B1 (ko) 2011-11-24 2014-08-07 주식회사 바이로메드 아데노바이러스 생산 신규 세포주 및 그의 용도
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
WO2013085624A1 (en) 2011-12-08 2013-06-13 Virovek, Inc. Vectors harboring toxic genes, methods and uses therefor
WO2013116591A1 (en) 2012-02-02 2013-08-08 Genvec, Inc. Adenoviral vector-based malaria vaccine
US9821114B2 (en) 2012-02-07 2017-11-21 Global Bio Therapeutics, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
WO2013135615A1 (en) 2012-03-12 2013-09-19 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
MY169331A (en) 2012-03-22 2019-03-21 Janssen Vaccines & Prevention Bv Vaccine against rsv
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EP2855669B1 (de) 2012-05-29 2018-10-10 GenVec, Inc. Modifizierte serotyp-28-adenovirusvektoren
US9676824B2 (en) 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine
US10357555B2 (en) 2012-07-10 2019-07-23 Transgene Sa Mycobacterial antigen vaccine
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
AU2013298632B2 (en) 2012-08-03 2018-11-01 Sanofi Pasteur Production of infectious influenza viruses
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
US9694050B2 (en) 2012-10-21 2017-07-04 University Of Rochester THY1 (CD90) as a novel therapy to control adipose tissue accumulation
CA2887711A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2015536147A (ja) 2012-11-16 2015-12-21 ベス イスラエル デアコネス メディカル センター インコーポレイテッド 組換えアデノウイルスおよびその使用
AU2013362134B2 (en) 2012-12-21 2018-07-05 Sykehuset Sorlandet Hf EGFR targeted therapy of neurological disorders and pain
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
KR101606910B1 (ko) 2013-03-29 2016-04-04 충북보건과학대학교 산학협력단 아데노바이러스 벡터 생산용 ａ５４９ 기반 세포주
EP3741385A1 (de) 2013-04-17 2020-11-25 Genzyme Corporation Zusammensetzungen zur anwendung in einem verfahren zur behandlung und vorbeugung von makuladegeneration
US9822418B2 (en) 2013-04-22 2017-11-21 Icahn School Of Medicine At Mount Sinai Mutations in PDGFRB and NOTCH3 as causes of autosomal dominant infantile myofibromatosis
KR102236497B1 (ko) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
US10294279B2 (en) 2013-06-17 2019-05-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
ES2525768B1 (es) * 2013-06-24 2015-10-07 Curaxis, S.L. Procedimiento para la producción de proteínas recombinantes glicosiladas.
CN105813579B (zh) 2013-08-08 2019-05-07 全球生物疗法有限公司 用于微创手术过程的夹具装置和其应用
AP2016009154A0 (en) 2013-09-19 2016-04-30 Crucell Holland Bv Improved adenovirus formulations
WO2015044418A1 (en) 2013-09-30 2015-04-02 Crucell Holland B.V. Method for the clarification of high density crude cell culture harvest
SG11201605595YA (en) 2014-01-09 2016-08-30 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
JP6719381B2 (ja) 2014-02-06 2020-07-08 ジェンザイム・コーポレーション 黄斑変性を処置し、予防するための組成物および方法
EP2927685A1 (de) 2014-04-02 2015-10-07 Medicyte GmbH Geeignete Hepatozyten für In-vitro-Hepatitistests
US10294460B2 (en) 2014-07-24 2019-05-21 Janssen Vaccines & Prevention B.V. Process for the purification of poliovirus from cell cultures
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
EP3194446B1 (de) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Zusammensetzungen und verfahren zur behandlung von fibrose
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
US10345259B2 (en) 2015-02-19 2019-07-09 Janssen Vaccines & Prevention B.V. Method for quantification of virus particles using capillary zone electrophoresis
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
JP6887955B2 (ja) 2015-03-18 2021-06-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 組換え体発現系のアッセイ
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
WO2016168601A1 (en) 2015-04-17 2016-10-20 Khalid Shah Agents, systems and methods for treating cancer
EP3285795B1 (de) 2015-04-22 2022-11-16 Cedars-Sinai Medical Center Enteral verabreichte bittere oligopeptide zur behandlung von typ-2-diabetes und fettleibigkeit
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
EP3319634B1 (de) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilisierte lösliche präfusionierte rsv-f-polypeptide
AU2016309743B2 (en) 2015-08-20 2019-02-07 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
WO2017060329A1 (en) 2015-10-06 2017-04-13 Janssen Vaccines & Prevention B.V. Methods for preventing plastic-induced degradation of biologicals
WO2017074517A1 (en) * 2015-10-30 2017-05-04 Seracare Life Sciences, Inc. Adenovirus control virus
EP3371211A4 (de) 2015-11-04 2019-08-21 Icahn School of Medicine at Mount Sinai Verfahren zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
US10377801B2 (en) 2015-11-04 2019-08-13 Northwestern University Amelioration of chronic kidney disease
SI3439672T1 (sl) 2016-04-05 2021-02-26 Janssen Vaccines & Prevention B.V. Stabiliziran topen pre-fuzijski F protein RSV za uporabo v profilaksi okužbe z RSV
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
US11246868B2 (en) 2016-04-26 2022-02-15 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
WO2017192418A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
CN109154000B (zh) 2016-05-12 2022-07-05 扬森疫苗与预防公司 有效和平衡的双向启动子
EA039124B1 (ru) 2016-05-30 2021-12-08 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные f-белки rsv до слияния
EP3472327B1 (de) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potenter und ausbalancierter bidirektionaler promotor
WO2018013509A1 (en) 2016-07-11 2018-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias
EP3484506A1 (de) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv-impfstoffe
US11155832B2 (en) 2016-09-30 2021-10-26 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into T cells
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
AU2018205496A1 (en) 2017-01-07 2019-07-25 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
WO2018140630A1 (en) 2017-01-25 2018-08-02 Northwestern University Autophagy inducers for treatment of cns conditions
BR112019015671A2 (pt) 2017-02-09 2020-04-14 Janssen Vaccines & Prevention Bv promotor potente e curto para expressão de genes heterológicos
JP2020507331A (ja) 2017-02-17 2020-03-12 ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ アデノ随伴ウイルスを生産するための哺乳動物細胞
CN110832072B (zh) 2017-04-21 2023-11-07 真基因太科公司 用于生产非复制型腺病毒的细胞系以及制备所述细胞系的方法
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
WO2019075360A1 (en) 2017-10-13 2019-04-18 Selecta Biosciences, Inc. METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES
CN111295391B (zh) 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途
MA50502A (fr) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv Adénovirus et utilisations associées
US11459583B2 (en) 2017-10-31 2022-10-04 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
JP7438943B2 (ja) 2017-10-31 2024-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルス及びその用途
EP3714043A4 (de) 2017-11-22 2021-08-11 The Regents of The University of Michigan Zusammensetzungen und verfahren zur behandlung von krebs
US11773142B2 (en) 2017-12-11 2023-10-03 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
PT3743106T (pt) 2018-01-23 2022-08-24 Janssen Vaccines & Prevention Bv Vacinas contra o vírus da influenza e suas utilizações
CA3092935A1 (en) 2018-03-06 2019-09-12 Precigen, Inc. Hepatitis b vaccines and uses of the same
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
WO2020216844A1 (en) 2019-04-25 2020-10-29 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
CN114126666A (zh) 2019-04-28 2022-03-01 西莱克塔生物科技公司 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法
AU2020275455A1 (en) 2019-05-15 2021-12-09 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CA3140234A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
WO2020229581A1 (en) 2019-05-16 2020-11-19 Janssen Vaccines & Prevention B.V. Methods for inducing a safe immune response against polio virus
BR112021023594A2 (pt) 2019-05-28 2022-02-08 Selecta Biosciences Inc Métodos e composições para resposta imune de vetor de transferência antiviral atenuada
JP2022547107A (ja) 2019-09-05 2022-11-10 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
JP2022551107A (ja) 2019-10-03 2022-12-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルスベクターおよびその使用
IL293051A (en) 2019-11-18 2022-07-01 Janssen Biotech Inc calr and jak2 mutant-based vaccines and their uses
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
EP4135757A1 (de) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma- und steap1-impfstoffe und ihre verwendungen
JP2023523919A (ja) 2020-04-21 2023-06-08 ジェイジェイピー バイオロジクス エスピー．ゼット オー．オー． ヒト化抗ヒトｃｄ８９抗体及びその使用
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
AU2021309007A1 (en) 2020-07-13 2023-02-16 Transgene Treatment of immune depression
AU2021324670A1 (en) 2020-08-11 2023-02-02 Musculoskeletal Transplant Foundation Method for treating cardiac conditions with placenta-derived compositions
WO2023017494A1 (en) 2021-08-13 2023-02-16 Triovance Holding Llc A skin substitute composition and methods of producing and using the same
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
EP4338727A1 (de) 2022-09-14 2024-03-20 Roquette Freres Adenovirus-formulierungen

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US545522A (en) * 1895-09-03 Vehicle-wheel
US4497796A (en) 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US4727028A (en) 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4487829A (en) * 1982-03-23 1984-12-11 Massachusetts Institute Of Technology Production and use of monoclonal antibodies against adenoviruses
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4517686A (en) * 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4740463A (en) 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
US5744133A (en) 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
US4835260A (en) 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5378618A (en) * 1988-04-15 1995-01-03 E. I. Du Pont De Nemours And Company Vitro headful packaging system for cloning DNA fragments as large as 95kb
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2000048A1 (en) * 1988-10-03 1990-04-03 Edward F. Plow Peptides and antibodies that inhibit integrin-ligand bindin g
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
GB8900483D0 (en) 1989-01-10 1989-03-08 Celltech Ltd Recombinant dna method
US5223394A (en) * 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
DE3923963A1 (de) 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5545522A (en) * 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
US6743623B2 (en) 1991-09-27 2004-06-01 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5518913A (en) 1991-10-10 1996-05-21 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
CA2053187A1 (en) 1991-10-10 1993-04-11 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
US5384249A (en) 1991-12-17 1995-01-24 Kyowa Hakko Kogyo Co., Ltd. α2→3 sialyltransferase
JPH08501686A (ja) 1992-09-25 1996-02-27 ローン−プーラン・ロレ・ソシエテ・アノニム 中枢神経系、特に脳における細胞への外来遺伝子の転移のためのアデノウィルスベクター
WO1994011506A1 (en) 1992-11-18 1994-05-26 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
AU680459B2 (en) * 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
ATE154200T1 (de) 1992-12-23 1997-06-15 Campina Melkunie Bv Verfahren zur gewinnung von alpha-lactalbumin und beta-lactoglobulin aus einem molkeproteinprodukt
WO1994023582A1 (en) * 1993-04-08 1994-10-27 Genetic Therapy, Inc. Adenoviral vectors including dna encoding lung surfactant protein
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
FR2704234B1 (fr) 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
ES2249761T3 (es) * 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
NZ269156A (en) * 1993-07-13 1996-03-26 Rhone Poulenc Rorer Sa Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy
FR2707664B1 (fr) 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5552311A (en) * 1993-09-14 1996-09-03 University Of Alabama At Birmingham Research Foundation Purine nucleoside phosphorylase gene therapy for human malignancy
US5534423A (en) * 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
US5658763A (en) 1993-10-25 1997-08-19 Creative Biomolecules, Inc. Methods and compositions for high protein production from non-native DNA
US6210939B1 (en) * 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US20010006629A1 (en) 1993-10-25 2001-07-05 Richard J. Gregory Recombinant adenoviral vector and methods of use
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
US6057299A (en) 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
WO1995026411A2 (en) 1994-03-25 1995-10-05 The Uab Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
US5789247A (en) 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
WO1995028938A1 (fr) 1994-04-26 1995-11-02 Chugai Seiyaku Kabushiki Kaisha Preparation de sucralfate granulee et fondue et son procede de production
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE336587T1 (de) * 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
FR2721943B1 (fr) 1994-06-29 1996-08-02 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour une superoxyde dismutase
ATE246252T1 (de) 1994-08-16 2003-08-15 Crucell Holland Bv Von adenovirus abgeleitete rekombinante vektoren, für gentherapie
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
FR2725726B1 (fr) * 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
CA2203809C (en) * 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
FR2726285B1 (fr) 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
CA2206205A1 (en) * 1994-11-28 1996-06-06 Genetic Therapy, Inc. Tissue-specific treatment, diagnostic methods, and compositions using replication-deficient vectors
WO1996018418A1 (en) * 1994-12-12 1996-06-20 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
FR2727867B1 (fr) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
GB9500659D0 (en) 1995-01-13 1995-03-08 Camco Drilling Group Ltd Improvements in or relating to rotary drill bits
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5652224A (en) * 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
DE69628744D1 (de) * 1995-04-17 2003-07-24 Univ Texas System Austin Board Adenovirus helfervirus system
JPH08303576A (ja) 1995-05-10 1996-11-19 Aisin Seiki Co Ltd 自動変速機の変速制御装置
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6265212B1 (en) * 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2735789B1 (fr) * 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US7001764B2 (en) 1995-06-27 2006-02-21 Cell Genesys, Inc. Compositions comprising tissue specific adenoviral vectors
FR2737222B1 (fr) * 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2737501B1 (fr) * 1995-07-31 1997-10-24 Transgene Sa Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants
US5622699A (en) * 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
DE69636122T2 (de) 1995-11-13 2006-12-07 Takara Bio Inc., Otsu Verfahren zum gentransfer in zielzellen mit einem retrovirus
US6140103A (en) * 1995-12-01 2000-10-31 Introgene B.V. Regulated protein expression in stably transfected mammalian cells
WO1997020575A1 (en) * 1995-12-08 1997-06-12 The University Of Alabama At Birmingham Research Foundation Targeted adenovirus vectors
EP0885307A1 (de) * 1996-02-09 1998-12-23 Vereniging Het Nederlands Kanker Instituut Vektoren und verfahren für die herstellung von zellen, die zusätzliches genetisches material in ihrem genom integriert enthalten.
CA2177085C (en) * 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US5922315A (en) * 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
EP0856585A1 (de) * 1997-01-29 1998-08-05 Introgene B.V. Ein induzierbares Replications- und Expressionssystem
ATE296117T1 (de) * 1997-03-07 2005-06-15 Wistar Inst Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben
CA2221819A1 (en) 1997-03-27 1998-09-27 Thomas A. Gigliatti Insect expression vectors
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
US5981275A (en) 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
IL132673A0 (en) 1997-05-08 2001-03-19 Genetic Therapy Inc Gene transfer with adenoviruses having modified fiber proteins
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
US6287857B1 (en) * 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
AU3358999A (en) 1998-03-20 1999-10-11 Genzyme Corporation Chimeric adenoviral vectors for targeted gene delivery
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) * 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
AU4682999A (en) 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1020529B1 (de) 1998-11-20 2005-06-01 Crucell Holland B.V. Genverabreichende Vektoren mit Gewebetropismus für glatte Muskelzellen und/oder Endothelzellen
EP1016726A1 (de) 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
DE60014489T3 (de) 1999-05-17 2010-08-12 Crucell Holland B.V. Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1067188A1 (de) 1999-07-08 2001-01-10 Introgene B.V. Infektion mit chimärischen Adenoviren der Zellen die für den Adenoviren Serotyp 5 Coxsacki Adenoviren Rezeptor (CAR) negativ sind
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
EP1103610A1 (de) 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
AU2001257611A1 (en) 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
EP1157999A1 (de) 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
US6844192B2 (en) 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
US20030026783A1 (en) 2001-08-03 2003-02-06 Amine Abina Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal transgenesis and in functional inactivation of an endogenous proteins
JP4583029B2 (ja) 2001-10-29 2010-11-17 クルセル ホランド ベー ヴェー 所定の翻訳後修飾を有する蛋白質の製造方法及び製造手段
AU2002351444B2 (en) 2001-12-07 2008-02-21 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
AU2002225509A1 (en) 2001-12-07 2003-06-17 Crucell Holland B.V. Production and of viruses, viral isolates and vaccines
JP4495588B2 (ja) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 安定なアデノウイルスベクターおよびその増殖方法
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
WO2004037294A2 (en) 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
NZ542585A (en) 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
KR20070104881A (ko) 2004-10-14 2007-10-29 크루셀 홀란드 비.브이. 말라리아 프라임/부스트 백신
US20070010016A1 (en) 2005-03-11 2007-01-11 Mccelland Alan Gene transfer with adenoviruses having modified fiber proteins

Also Published As

Publication number Publication date
DE69633565D1 (de) 2004-11-11
US6238893B1 (en) 2001-05-29
EP0833934A1 (de) 1998-04-08
JP4051416B2 (ja) 2008-02-27
DK0833934T3 (da) 2005-02-07
CA2222140C (en) 2010-11-23
US20020151032A1 (en) 2002-10-17
IL122614A0 (en) 1998-08-16
HK1064406A1 (en) 2005-01-28
ES2231813T3 (es) 2005-05-16
US6306652B1 (en) 2001-10-23
KR20040065317A (ko) 2004-07-21
US20090023196A1 (en) 2009-01-22
KR100470180B1 (ko) 2005-02-04
US6033908A (en) 2000-03-07
DE69633565T2 (de) 2005-12-22
EP0833934B1 (de) 2004-10-06
EP1445322B2 (de) 2012-06-06
EP1445322B1 (de) 2009-10-14
ES2231813T5 (es) 2012-12-17
EP0833934B2 (de) 2012-08-15
KR100449181B1 (ko) 2005-01-24
CA2222140A1 (en) 1997-01-03
ATE278794T1 (de) 2004-10-15
US20020164802A1 (en) 2002-11-07
IL160406A (en) 2008-03-20
IL160406A0 (en) 2004-07-25
SI0833934T2 (sl) 2013-04-30
ATE445705T1 (de) 2009-10-15
US5994128A (en) 1999-11-30
PT1445322E (pt) 2010-01-19
ES2333425T5 (es) 2012-08-28
SI0833934T1 (en) 2005-02-28
DK0833934T4 (da) 2012-11-19
ES2333425T3 (es) 2010-02-22
WO1997000326A1 (en) 1997-01-03
US6602706B1 (en) 2003-08-05
US8236293B2 (en) 2012-08-07
US20050221492A1 (en) 2005-10-06
EP1445322A1 (de) 2004-08-11
DK1445322T4 (da) 2012-09-03
SI1445322T1 (sl) 2010-01-29
DE69633565T3 (de) 2013-01-17
JP2006345872A (ja) 2006-12-28
DK1445322T3 (da) 2010-01-04
AU6018296A (en) 1997-01-15
JPH11507552A (ja) 1999-07-06
PT833934E (pt) 2005-02-28
AU731767B2 (en) 2001-04-05
SI1445322T2 (sl) 2012-10-30
KR19990022941A (ko) 1999-03-25
US6395519B1 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
ATE445705T1 (de) Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
Chew et al. Innate and adaptive immune responses to herpes simplex virus
HUP0104609A2 (hu) Plazmidfenntartó rendszer antigén-bejuttatásra
DE69806408D1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
Liu et al. Promising cytomegalovirus-based vaccine vector induces robust CD8+ T-cell response
NO904538D0 (no) Kimaere glykoproteiner inneholdende immunogene segmenter av humant parainfluensavirus type 3.
AP2000001841A0 (en) Method for obtaining vaccines for preventing the pathgenic effects related to a retroviral infection.
Varon et al. Helicobacter pullorum cytolethal distending toxin targets vinculin and cortactin and triggers formation of lamellipodia in intestinal epithelial cells
ATE297750T1 (de) Verwendung von hsp70 protein
EP0319570A4 (en) Recombinant human cytomegalovirus containing foreign gene and use thereof
Strazic Geljic et al. Viral interactions with adaptor-protein complexes: a ubiquitous trait among viral species
DK0892054T3 (da) Clostridium perfringens-vaccine
ES2194012T3 (es) Epitopo p1a1 y p1a2 de la gpiii a de plaquetas, su preparacion y uso.
PT880594E (pt) Vector retroviral e sua utilizacao em terapia genica
WO2001044280A3 (en) Methods and compositions for the manufacture of replication incompetent adenovirus
Ossevoort et al. Characterization of an immuno ‘stealth’derivative of the herpes simplex virus thymidine-kinase gene
BR9912719A (pt) Processo para propagar um vìrus do herpes mutante, uso de uma linhagem de célula, linhagem de célula, vìrus, e, composição farmacêutica
DE69428984D1 (de) Stimulierung der immunantwort durch virales protein
Zou et al. α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants
Ramos-Gonzalez et al. Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth
Farzad et al. Feasibility of applying helper-dependent adenoviral vectors for cancer immunotherapy
ATE334207T1 (de) Zellzikluskontrollpunkt-spezifische gene
Cheroutre HIV vaccination: turning the spotlight on effector memory T cells as mucosal gatekeepers

Legal Events

Date Code Title Description
8363 Opposition against the patent